» Articles » PMID: 20230542

Autosomal Dominant Polycystic Kidney Disease: Risk Factor for Nonmelanoma Skin Cancer Following Kidney Transplantation

Overview
Journal Transpl Int
Specialty General Surgery
Date 2010 Mar 17
PMID 20230542
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Nonmelanoma skin cancers (NMSC) are the most common malignant tumors following solid organ transplantation. Risk factors for NMSC mainly include immunosuppression, age, sun exposure and patient phototype. Recent findings have suggested that autosomal dominant polycystic kidney disease (ADPKD) may increase the risk of developing NMSC. We performed a monocenter retrospective study including all kidney recipients between 1985 and 2006 (n = 1019). We studied the incidence of NMSC, solid cancers and post-transplantation lymphoproliferative disease (PTLD), and analyzed the following parameters: age, gender, phototype, time on dialysis, graft rank, immunosuppressive regimen, history of cancer and kidney disease (ADPKD versus others). Median follow-up was 5.5 years (range: 0.02-20.6; 79 838 patient-years). The cumulated incidence of NMSC 10 years after transplantation was 12.7% (9.3% for solid cancers and 3.5% for PTLD). Autosomal dominant polycystic kidney disease and age were risk factors for NMSC (HR 2.63; P < 0.0001 and HR 2.21; P < 0.001, respectively) using univariate analysis. The association between ADPKD and NMSC remained significant after adjustments for age, gender and phototype using multivariate analysis (HR 1.71; P = 0.0145) and for immunosuppressive regimens (P < 0.0001). Autosomal dominant polycystic kidney disease was not a risk factor for the occurrence of solid cancers after transplantation (HR 0.96; P = 0.89). Our findings suggest that ADPKD is an independent risk factor for developing NMSC after kidney transplantation.

Citing Articles

Thiazides in kidney transplant recipients: skin in the game.

van Laecke S Nat Rev Nephrol. 2024; 20(6):351-352.

PMID: 38632382 DOI: 10.1038/s41581-024-00839-9.


Leukopenia in autosomal dominant polycystic kidney disease: a single-center cohort of kidney transplant candidates with post-transplantation follow-up.

Schellekens P, Van Loon E, Coemans M, Meyts I, Vennekens R, Kuypers D Clin Kidney J. 2023; 16(12):2578-2586.

PMID: 38046014 PMC: 10689124. DOI: 10.1093/ckj/sfad165.


Mortality among solid organ transplant recipients with a pretransplant cancer diagnosis.

Hart A, Pfeiffer R, Morawski B, Lynch C, Zeng Y, Pawlish K Am J Transplant. 2023; 23(2):257-264.

PMID: 36804133 PMC: 9978936. DOI: 10.1016/j.ajt.2022.11.006.


Outcomes of Kidney Transplantation in Patients with Autosomal Dominant Polycystic Kidney Disease: Our Experience Based on 35-Years Follow-Up.

Tsai T, Chen C, Wu M, Tsai S Diagnostics (Basel). 2022; 12(5).

PMID: 35626329 PMC: 9139921. DOI: 10.3390/diagnostics12051174.


Novel non-cystic features of polycystic kidney disease: having new eyes or seeking new landscapes.

van Laecke S, Van Biesen W Clin Kidney J. 2021; 14(3):746-755.

PMID: 33777359 PMC: 7986322. DOI: 10.1093/ckj/sfaa138.